Hunting ecology predicts eye arrangements in the modular visual system of spiders

Posted by
  Hunting ecology predicts eye arrangements in the modular visual system of spiders Summary Vision is one of the most important senses used by animals and contributes to fundamental behaviors, including foraging, navigation, and mate detection and selection. 1 Although much is known about how eye position and orientation correlate to ecology in the context of binocularity, 2 animals with multipartite visual systems (more than two eyes) remain comparatively neglected. Spiders are highly successful predators that occupy a range of ecological niches and usually possess eight eyes. Here, we use three-dimensional geometric morphometrics and evolutionary modeling to test whether eye positions, orientations, and interocular angles correlate with hunting strategies in 52 species across the spider phylogeny. We demonstrate that eye configurations diversified from an ancestral medial cluster, as seen in modern trapdoor spiders, to a halo-like configuration in orb-weavers, and to the fronta...

Successful venom immunotherapy with avapritinib in a patient with systemic mastocytosis

Posted by

 


Successful venom immunotherapy with avapritinib in a patient with systemic mastocytosis

Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by tissue infiltration of MCs driving clinical symptoms.1 The disorder is characterized by activating mutations in the KIT protein, classically KIT p.D816V. SM is treated in a symptom-guided manner with therapies targeted toward bioactive MC mediators. However, the recent discoveries of targeted tyrosine kinase inhibitors have changed the treatment paradigm of indolent SM (ISM).2 Tyrosine kinase inhibitors have demonstrated to reduce MC burden and improve quality of life. To date, they have not been used to facilitate venom immunotherapy (VIT). Patients with mastocytosis and Hymenoptera venom allergy may have recurrent anaphylaxis during VIT, and adjunctive therapies are a significant unmet need to protect this patient population. Although omalizumab has been found to be effective in a subset of patients, non-IgE-mediated mechanisms may be activated by Hymenoptera venom and an increased mutated MC burden may contribute to life-threatening symptoms. We report, here, the first case of successful VIT in a patient with ISM treated with avapritinib.

Depina, L., Karmarkar, S. N., Moeller, S., Lazarovich, M., De Magalhães, A. R., Castells, M., & Giannetti, M. P. (2025). Successful venom immunotherapy with avapritinib in a patient with systemic mastocytosis. Annals of Allergy, Asthma & Immunology, 135(3), 343-344. https://doi.org/10.1016/j.anai.2025.06.015